What are the indications, dosing, and potential complications of Amphotericin B (antifungal medication)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amphotericin B: Indications, Dosing, and Complications

Amphotericin B should be used primarily for treatment of progressive and potentially life-threatening fungal infections, with conventional amphotericin B administered at 0.5-1.5 mg/kg daily intravenously or lipid formulations at 3-5 mg/kg daily depending on the specific infection and patient factors. 1, 2

Indications

  • Indicated for treatment of progressive and potentially life-threatening fungal infections; should not be used for noninvasive fungal diseases such as oral thrush, vaginal candidiasis, or esophageal candidiasis in patients with normal neutrophil counts 2
  • Primary indications include:
    • Invasive candidiasis and candidemia 1
    • Invasive aspergillosis 2, 3
    • Cryptococcal meningitis 3
    • Sporotrichosis (cutaneous, lymphocutaneous, pulmonary, meningeal, or disseminated) 1
    • Mucormycosis/rhinocerebral phycomycosis 2
    • Empiric therapy in febrile neutropenic patients 1, 4

Formulations and Dosing

Conventional Amphotericin B (Deoxycholate)

  • Standard dosage: 0.5-1.5 mg/kg administered once daily intravenously over 1-2 hours 1, 3
  • For severe or life-threatening infections: 0.7-1.0 mg/kg daily 1
  • For neonates with disseminated candidiasis: 1 mg/kg daily 1, 3
  • Maximum daily dose should never exceed 1.5 mg/kg due to risk of potentially fatal cardiac or cardiopulmonary arrest 2
  • Recommended concentration for IV infusion: 0.1 mg/mL 1, 2
  • Initial test dose recommended: 1 mg in 20 mL of 5% dextrose solution administered over 20-30 minutes 2

Lipid Formulations of Amphotericin B

  • Three main lipid formulations available with different properties:
    • Liposomal Amphotericin B (AmBisome): 3-5 mg/kg daily IV 1, 3
    • Amphotericin B Lipid Complex (ABLC): 5 mg/kg daily IV 1, 3
    • Amphotericin B Colloidal Dispersion (ABCD): 3-6 mg/kg daily IV 3, 5
  • Lipid formulations are preferred in patients with renal impairment or those who experience toxicity with conventional amphotericin B 5, 6
  • Liposomal amphotericin B provides the greatest renal protection among lipid formulations 5, 6

Duration of Therapy

  • For candidemia: Continue treatment for 14 days after the last positive blood culture and resolution of signs and symptoms 1, 3
  • For sporotrichosis: At least 12 months of therapy 1
  • For disseminated candidiasis: Treatment until all signs and symptoms of infection have resolved 1
  • For cryptococcal meningitis: At least 2 weeks followed by fluconazole 3
  • For rhinocerebral phycomycosis: Cumulative dose of at least 3g recommended 2

Complications and Adverse Effects

Nephrotoxicity

  • Primary toxicity is nephrotoxicity, defined by substantial azotemia from glomerular damage 1
  • Often accompanied by hypokalemia from tubular damage 1
  • Exacerbated by concomitant use of other nephrotoxic drugs 1
  • Permanent nephrotoxicity related to cumulative dose 1
  • Can be ameliorated by hydration with 0.9% saline IV 30 minutes before infusion 1, 3
  • Lipid formulations have significantly less nephrotoxicity compared to conventional amphotericin B 5, 6, 4

Infusion-Related Reactions

  • Fever, chills, nausea, and vomiting commonly occur during infusion 1
  • Typically begin within 1-3 hours after infusion starts and last <1 hour 1
  • Less frequent in children than adults 1
  • Tend to decrease in frequency over time 1
  • Can be alleviated by pretreatment with acetaminophen or diphenhydramine 1, 3
  • Significantly fewer infusion-related reactions with lipid formulations, particularly liposomal amphotericin B 6, 4

Other Adverse Effects

  • Idiosyncratic reactions: hypotension, arrhythmias, allergic reactions including anaphylaxis 1
  • Hepatic toxicity 1
  • Thrombophlebitis 1
  • Anemia 1
  • Neurotoxicity (rare): confusion, delirium, hearing loss, blurred vision, seizures 1
  • Overdose can result in potentially fatal cardiac or cardiopulmonary arrest 2

Special Populations

Pediatric Patients

  • For children: 0.5-1.5 mg/kg daily IV or 50 mg/m²/day 1, 3
  • For neonates with disseminated candidiasis: 1 mg/kg daily IV 1
  • In patients with azotemia, hyperkalemia, or receiving high doses (>1 mg/kg), a longer infusion time of 3-6 hours is recommended 1

Pregnant Women

  • Amphotericin B is the preferred antifungal for severe fungal infections during pregnancy 1
  • Lipid formulations at 3-5 mg/kg daily are recommended 1
  • Azoles should be avoided during pregnancy 1

Monitoring

  • Monitor renal function, electrolytes, and liver function tests regularly 3
  • For patients with persistent candidemia despite appropriate therapy, investigate for deep tissue focus of infection 1
  • In neonates with candidemia, perform lumbar puncture, dilated retinal examination, and imaging of genitourinary tract, liver, and spleen 1

Important Considerations

  • Central venous catheters should be removed when feasible in patients with fungemia 1
  • For patients with mild-to-moderate disease, consider initiating at lower doses (0.25-0.5 mg/kg) and increasing as tolerated 1
  • For life-threatening disease, target daily dose should be administered from the beginning 1
  • Following stabilization and resolution of fever, amphotericin B can be administered as 1.5 mg/kg IV once every other day 1
  • Combination therapy with flucytosine (100-150 mg/kg/day divided into 4 doses) may be considered for severe invasive candidiasis, particularly in CNS disease 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.